Jain Chung

3.4k total citations · 2 hit papers
16 papers, 2.4k citations indexed

About

Jain Chung is a scholar working on Infectious Diseases, Virology and Surgery. According to data from OpenAlex, Jain Chung has authored 16 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Virology and 2 papers in Surgery. Recurrent topics in Jain Chung's work include HIV Research and Treatment (8 papers), HIV/AIDS Research and Interventions (8 papers) and HIV/AIDS drug development and treatment (7 papers). Jain Chung is often cited by papers focused on HIV Research and Treatment (8 papers), HIV/AIDS Research and Interventions (8 papers) and HIV/AIDS drug development and treatment (7 papers). Jain Chung collaborates with scholars based in United States, Switzerland and United Kingdom. Jain Chung's co-authors include Miklos Salgo, Ralph DeMasi, Jonathan Hauptman, Charles Lucas, David C. Robbins, Douglas C. Heimburger, Mario DiGirolamo, Steven B. Heymsfield, Charles H. Halsted and John P. Foreyt and has published in prestigious journals such as New England Journal of Medicine, JAMA and Diabetes Care.

In The Last Decade

Jain Chung

14 papers receiving 2.2k citations

Hit Papers

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistan... 1999 2026 2008 2017 2003 1999 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jain Chung United States 10 991 852 826 532 483 16 2.4k
Caroline Perry United States 19 334 0.3× 343 0.4× 137 0.2× 591 1.1× 122 0.3× 48 1.8k
D.J. Back United Kingdom 29 197 0.2× 596 0.7× 347 0.4× 346 0.7× 51 0.1× 80 2.2k
Stephen S. Hwang United States 17 113 0.1× 531 0.6× 812 1.0× 54 0.1× 185 0.4× 38 1.8k
Juan J.L. Lertora United States 24 126 0.1× 399 0.5× 166 0.2× 93 0.2× 93 0.2× 49 1.7k
Vicente Estrada Spain 28 52 0.1× 1.5k 1.8× 1.1k 1.4× 135 0.3× 192 0.4× 113 2.6k
Anne Marie Comeau United States 28 106 0.1× 795 0.9× 499 0.6× 33 0.1× 237 0.5× 68 3.0k
James R. Lane United States 21 177 0.2× 664 0.8× 507 0.6× 24 0.0× 55 0.1× 68 1.8k
Peter P. Koopmans Netherlands 24 106 0.1× 1.5k 1.8× 1.1k 1.3× 32 0.1× 103 0.2× 54 2.5k
P. H. P. Groeneveld Netherlands 24 64 0.1× 454 0.5× 189 0.2× 62 0.1× 105 0.2× 54 1.4k
Joanne V. Mei United States 19 76 0.1× 446 0.5× 316 0.4× 69 0.1× 103 0.2× 35 1.3k

Countries citing papers authored by Jain Chung

Since Specialization
Citations

This map shows the geographic impact of Jain Chung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jain Chung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jain Chung more than expected).

Fields of papers citing papers by Jain Chung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jain Chung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jain Chung. The network helps show where Jain Chung may publish in the future.

Co-authorship network of co-authors of Jain Chung

This figure shows the co-authorship network connecting the top 25 collaborators of Jain Chung. A scholar is included among the top collaborators of Jain Chung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jain Chung. Jain Chung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Lee, Eunkyung, et al.. (2025). Recruitment Feasibility of Hispanic Women in Breast Cancer Survivorship Research Using State Cancer Registry Procedures. Journal of Racial and Ethnic Health Disparities.
2.
O’Hearn, Mary, Jain Chung, Peter J. Piliero, et al.. (2020). Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. UNC Libraries.
3.
Cooper, DA, Peter Reiss, Keith Henry, et al.. (2010). The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy*. HIV Medicine. 12(1). 31–39. 12 indexed citations
4.
Wright, David H., Eliot Godofsky, Sharon Walmsley, et al.. (2008). Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected Patients. HIV Clinical Trials. 9(2). 73–82. 10 indexed citations
5.
Mayers, Douglas L., Jain Chung, Veronika Kohlbrenner, et al.. (2006). Seeking Ethical Designs for HIV Clinical Trials in Treatment-Experienced Patients: An Industry Perspective. AIDS Research and Human Retroviruses. 22(11). 1110–1112. 1 indexed citations
6.
Raffi, F., Christine Katlama, Michael S. Saag, et al.. (2006). Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) Trials. Clinical Infectious Diseases. 42(6). 870–877. 37 indexed citations
7.
Huson, Les, Jain Chung, & Miklos Salgo. (2006). Multiple Polyexponentials and Quasipolynomials as Empirical Nonlinear Regression Models: A Case Study with HIV Viral Load Data. Journal of Biopharmaceutical Statistics. 16(2). 165–179. 2 indexed citations
8.
Huson, Les, Jain Chung, & Miklos Salgo. (2006). Missing Data Imputation in Two Phase III Trials Treating HIV1 Infection. Journal of Biopharmaceutical Statistics. 17(1). 159–172. 9 indexed citations
9.
Montaner, Julio, et al.. (2005). Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 Disease. HIV Clinical Trials. 6(6). 281–290. 16 indexed citations
10.
Matthews, Thomas J., Miklos Salgo, Michael Greenberg, et al.. (2004). Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Reviews Drug Discovery. 3(3). 215–225. 362 indexed citations
11.
Lalezari, Jacob, Keith Henry, Mary O’Hearn, et al.. (2003). Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. New England Journal of Medicine. 348(22). 2175–2185. 716 indexed citations breakdown →
12.
Chung, Jain, Herbert Birnböck, Berthold Lausecker, et al.. (2000). Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. British Journal of Clinical Pharmacology. 49(3). 231–239. 3 indexed citations
13.
Davidson, Michael, Jonathan Hauptman, Mario DiGirolamo, et al.. (1999). Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat. JAMA. 281(3). 235–235. 705 indexed citations breakdown →
14.
Hollander, Priscilla, Steven C. Elbein, Irl B. Hirsch, et al.. (1998). Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study. Diabetes Care. 21(8). 1288–1294. 472 indexed citations
15.
Chung, Jain, et al.. (1989). A Simple Method for Computing the Arl of [ILM0001]-Charts with Zone Tests. Communications in Statistics - Simulation and Computation. 18(4). 1275–1293. 1 indexed citations
16.
Reynolds, Marion R. & Jain Chung. (1986). Regression methodology for estimating model prediction error. Canadian Journal of Forest Research. 16(5). 931–938. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026